VIATRIS INC. for VIATRIS INC
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 21, 2021 | $550,000 | Replaced |
| 4th Quarter - Amendment (this page) | Feb 2, 2021 | $580,000 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
H.R. 6930 - Made in America Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| AKSHAI DATTA | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
| ANNE WILSON | — |
Financial Institutions/Investments/Securities FIN
Policy related to corporate governance
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID MARIN | — |
Budget/Appropriations BUD
Medicaid Rebate provision of the Bipartisan Budget Act of 2015
| Lobbyist | Covered position, as disclosed |
|---|---|
| AKSHAI DATTA | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
| ANNE WILSON | — |
Trade (domestic/foreign) TRD
Trade issues related to generic medicines Access to global pharmaceutical supply chain and incentives for domestic manufacturing
| Lobbyist | Covered position, as disclosed |
|---|---|
| AKSHAI DATTA | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
| ANNE WILSON | — |
Copyright/Patent/Trademark CPT
Issues related Inter Partes Review (IPR) process for biosimilars and generic drugs S.344, H.R. 990 - Hatch-Waxman Integrity Act of 2019 Patent Settlements Patent Reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| AKSHAI DATTA | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
Health Issues HCR
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Generic drug quality and FDA oversight Medicare reimbursement for biosimilars, shared savings for Part B providers S.2543 - Prescription Drug Pricing Reduction Act S. 1416 - Affordable Prescriptions for Patients Act S. 1895 - Lower Health Care Costs Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R. 938 - BLOCKING Act of 2019 H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019 Part D Formulary Design and Generic Drug Tiering H.R. 4913 - Ensuring Access to Lower-Cost Medicines for Seniors Act H.R. 4455 - BIOSIM Act H.R. 4629 - Star Rating for Biosimilars Act H.R. 6179 - Increasing Access to Biosimilars Act of 2020 S. 2723 - Mitigating Emergency Drug Shortages Act H.R. 5304 - PBM Transparency in Prescription Drug Costs Act H.R. 748 - CARES Act H.R. 6431 - Made in America Emergency Preparedness Act S. 4134 - Increasing Access to Biosimilars Act of 2020 Electronic Labeling of Prescription Drugs H.R. 133 - Consolidated Appropriations Act, 2021 H.R. 2375 - Preserve Access to Affordable Generics and Biosimilars Act H.R. 8644 - Secure Americas Medicine Act of 2020 H.R. 8588 - Improving the American Drug Supply Chain Act of 2020
| Lobbyist | Covered position, as disclosed |
|---|---|
| AKSHAI DATTA | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
| ANNE WILSON | — |
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.